Group 1 - The company reported Q4 revenues of $14.89 billion, representing a 25% year-on-year increase [1] - Operating profit for the quarter was $2 billion, up 79% compared to the previous year [1] - Earnings per share (EPS) reached $0.97, reflecting a 71% increase year-on-year [1] Group 2 - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts and buy/sell ratings [1] - The group offers detailed product sales forecasts and integrated financial statements for major pharmaceutical companies [1] - The lead consultant, Edmund Ingham, has extensive experience in biotech and healthcare, having compiled reports on over 1,000 companies [1]

Core Viewpoint - Healthcare companies exhibit low correlation with macroeconomic factors, making them an attractive investment option [1] Summary by Category - **Stock Prices**: The stock prices referenced were the afternoon prices on February 15, 2025, indicating a specific timeframe for the analysis [1] - **Publication Date**: The video discussing these insights was published on February 17, 2025, providing context for the timing of the information [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

What science can do AstraZeneca Annual Report and Form 20-F Information 2024 Welcome What science can do We are a global, science-led, patient-focused pharmaceutical business, committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life. Our sustainability reporting Our sustainability reporting is prepared in line with the UK Companies Act 2006, sections 414CA and 414CB. In ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/astrazeneca-plc-l ...

NEW YORK, Feb. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fe ...

Core Viewpoint - Rosen Law Firm is reminding purchasers of AstraZeneca PLC securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the AstraZeneca securities class action is from February 23, 2022, to December 17, 2024 [1]. - Investors who purchased AstraZeneca securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 21, 2025 [3]. Group 2: Legal Allegations - The lawsuit alleges that AstraZeneca made materially false and misleading statements and failed to disclose significant issues, including engaging in insurance fraud in China [5]. - As a result of these actions, AstraZeneca faced increased legal exposure in China, leading to the detention of its China President by law enforcement [5]. - The lawsuit claims that the true details, once revealed, could materially harm AstraZeneca's business activities in China, resulting in damages to investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].

Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're already doing better in 2025, though. And there are good reasons to think both could maintain a strong performance throughout the year. Here's why. 1. Vertex PharmaceuticalsVertex Pharmaceuticals performed well for much of 2024. The stock slid during the year's final months, culminating in a massive one-day drop prom ...

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/astrazeneca-plc-l ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company engaged in insurance fraud in China, leading to legal exposure and potential harm to its business activities in the region [1]. Group 1: Allegations - The complaint alleges that during the class period from February 23, 2022, to December 17, 2024, AstraZeneca made materially false and misleading statements [1]. - Specific allegations include that AstraZeneca engaged in insurance fraud in China, which resulted in the detention of the AstraZeneca China President by law enforcement [1]. - The lawsuit claims that AstraZeneca understated its legal risks, and the revelations could materially harm the company's business activities in China [1]. Group 2: Class Action Details - Shareholders who purchased shares of AstraZeneca during the specified class period are encouraged to register for the class action, with a deadline of February 21, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].